http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6180600-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5e95156255d5fe8b2923c544786e176 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1013 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-103 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate | 1996-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2001-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8cb33c629853379142fd607f735365a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cb025c5bf6f6e9bc836f800831ea9c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e173492b1331761d49521a95b9e48827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec970a487e23604744623df43deb5331 |
| publicationDate | 2001-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-6180600-B1 |
| titleOfInvention | CD8 antagonists |
| abstract | Compounds that inhibit CD8 mediated T cell activation and that have a molecular surface that corresponds to the molecular surface of human CD8 at amino acids 38-46 and/or 53-56 and/or 60-67 and pharmaceutical compositions comprising such compounds are disclosed. Methods of inhibiting activation of a human T cell are disclosed. The methods comprise contacting a T cell with a compound that inhibits CD8 mediated T cell activation and that has a molecular surface that corresponds to the molecular surface of human CD8 at amino acids 38-46 and/or 53-56 and/or 60-67. Methods of treating an individual suspected of suffering from or susceptible to graft versus host disease and/or organ rejection are disclosed. The methods comprise administering an effective amount of a compound that inhibits CD8 mediated T cell activation and that has a molecular surface that corresponds to the molecular surface of human CD8 at amino acids 34-46 and/or 53-56 and/or 60-67. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7053043-B1 |
| priorityDate | 1995-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 228.